Business Wire

Primex Pharmaceuticals at Euroanaesthesia 2017: Next Innovation in the Management of Paediatric Sedation

Jaa

With a growing number of surgical and diagnostic procedures being performed globally, children are subjected to increased levels of anxiety that may occur before anaesthesia or thereafter, leading to behavioural stress and frightened, phobic and non-cooperative children with traumas.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170605005326/en/

Dr. Michael Brackhahn (Photo: Business Wire)

Dr. Michael Brackhahn (Photo: Business Wire)

Premedication may be administered to reduce the preoperative anxiety. However, one of the challenges facing paediatric anaesthesiologists is the lack of suitable medications, either due to their lack of acceptability, or their being unregistered and therefore used outside of their medical indication.

An innovative oral solution for children, ADV6209, has been developed to improve the management of paediatric sedation.

Dr. Michael Brackhahn from the Department of Anaesthesiology at the Children’s Hospital ‘Auf der Bult’ in Hannover, Germany, presented results from the clinical and PK studies along with his own experience of ADV6209 in procedural sedation. The results show the rapid sedative effect by paediatric patients in clinical practice as one of the main advantages of this formulation.

"ADV6209 is an oral solution and is currently under regulatory submission in the EU. We are excited to bring the next anaesthetic innovation to the market”, said Mr. Alan Knox, Head of Global Marketing at Primex Pharmaceuticals. "Anaesthesiologists have been asking for a licensed paediatric sedative that is well accepted by children, and would thereby evolve the management of procedural sedation, such as in emergency and diagnostic procedures."

Mr. Kari Sarvanto, CEO and Co-Founder of Primex, added: “Primex is proud to bring a patient-friendly oral solution to a market with such an unmet need. We are committed to making Primex Pharmaceuticals the leading global anaesthesia pharmaceutical company, and we aim to expand further into paediatrics and into orphan pharmaceuticals.”

About Primex Pharmaceuticals:

Primex Pharmaceuticals is a leading innovative anaesthesia company. A strong trusted anaesthesia portfolio is helping patients undergo a wide range of medical procedures. Primex Pharmaceuticals will continue to identify, acquire and bring to the market new medications that complete the ‘Triad of Anaesthesia’.

Primex Pharmaceuticals' global partner network operates in over 40 countries. The company is headquartered in Switzerland; all Primex products are manufactured in Europe.

www.primexpharma.com

http://euroanaesthesia2017.esahq.org/

Contact information

Primex Pharmaceuticals
Mr. Kari Sarvanto, CEO
Mobile: +41 796 162 694
Email: kari.sarvanto@primexintl.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201721.10.2017 00:00Tiedote

Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are

More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 18:08Tiedote

The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 15:15Tiedote

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 15:03Tiedote

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 13:47Tiedote

SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme